Neonatal screening for cystic fibrosis: Comparing the performances of IRT/DNA and IRT/PAP

Journal of Cystic Fibrosis

Volumn 13, Issue 4, 2014, Pages 384-390

  Sarles, Jacques ^b,e   Giorgi, Roch ^a,b   Berthézène, Patrice ^c   Munck, Anne ^e,f   Cheillan, David ^e,g   Dagorn, Jean Charles ^c   Roussey, Michel ^d,e  

^a AIX MARSEILLE UNIV   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

^d SERVICE DE RHUMATOLOGIE   (France)

^e AFDPHE   (France)

^f ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^g CarMeN   (France)

Author keywords

CFTR; Cystic fibrosis; IRT; Neonatal screening; Non inferiority; PAP

Indexed keywords

DNA; IMMUNOREACTIVE TRYPSINOGEN; PANCREATITIS ASSOCIATED PROTEIN; TRYPSINOGEN; UNCLASSIFIED DRUG; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; LECTIN; PANCREATITIS-ASSOCIATED PROTEIN; TUMOR ANTIGEN; TUMOR MARKER;

ARTICLE; CYSTIC FIBROSIS; DNA DETERMINATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IONTOPHORESIS; MAJOR CLINICAL STUDY; MECONIUM ILEUS; NEWBORN; NEWBORN SCREENING; SWEAT TEST; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; FEMALE; FOLLOW UP; GENETIC SCREENING; GENETICS; MALE; METABOLISM; MULTICENTER STUDY; MUTATION; NUCLEOTIDE SEQUENCE; PROCEDURES; RETROSPECTIVE STUDY;

ANTIGENS, NEOPLASM; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DNA; DNA MUTATIONAL ANALYSIS; FEMALE; FOLLOW-UP STUDIES; GENETIC TESTING; HUMANS; INFANT, NEWBORN; LECTINS, C-TYPE; MALE; MUTATION; NEONATAL SCREENING; RETROSPECTIVE STUDIES; TRYPSINOGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84902323785     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2014.01.004     Document Type: Article

References (18)

1. Munck A., Dhondt J.L., Sahler C., Roussey M. Implementation of the French nationwide cystic fibrosis newborn screening program. J Pediatr 2008, 153:228-233.
2. Munck A., Roussey M. The French natiowide cystic fibrosis newborn screening program: strategy and results. Arch Pediatr 2008, 15(Suppl. 1):S1-S6.
3. Wilcken B., Wiley V. Newborn screening methods for cystic fibrosis. Paediatr Respir Rev 2003, 4:272-277.
4. Comeau A.M., Accurso F.J., White T.B., Campbell P.W., Hoffman G., Parad R.B., et al. Guidelines for implementation of cystic fibrosis newborn screening programs: Cystic Fibrosis Foundation workshop report. Pediatrics 2007, 119:e495-e518.
5. Castellani C., Southern K.W., Brownlee K., Dankert Roelse J., Duff A., Farrell M., et al. European best practice guidelines for cystic fibrosis neonatal screening. J Cyst Fibros 2009, 8:153-173.
6. Iovanna J.L., Ferec C., Sarles J., Dagorn J.C. The pancreatitis-associated protein (PAP). A new candidate for neonatal screening of cystic fibrosis. C R Acad Sci III 1994, 317:561-564.
7. Sarles J., Berthezene P., Le Louarn C., Somma C., Perini J.M., Catheline M., et al. Combining immunoreactive trypsinogen and pancreatitis-associated protein assays, a method of newborn screening for cystic fibrosis that avoids DNA analysis. J Pediatr 2005, 147:302-305.
8. Vernooij-van Langen A.M., Loeber J.G., Elvers B., Triepels R.H., Gille J.J., Van der Ploeg C.P., et al. Novel strategies in newborn screening for cystic fibrosis: a prospective controlled study. Thorax 2012, 67:289-295.
9. Cornel M.C., Gille J.J., Loeber J.G., Vernooij-van Langen A.M., Dankert-Roelse J., Bolhuis P.A. Improving test properties for neonatal cystic fibrosis screening in the Netherlands before the nationwide start by May 1st 2011. J Inherit Metab Dis 2012, 35:635-640.
10. Sommerburg O., Lindner M., Muckenthaler M., Kohlmueller D., Leible S., Feneberg R., et al. Initial evaluation of a biochemical cystic fibrosis newborn screening by sequential analysis of immunoreactive trypsinogen and pancreatitis-associated protein (IRT/PAP) as a strategy that does not involve DNA testing in a Northern European population. J Inherit Metab Dis 2010, 33(Suppl. 2):S263-S271.
11. D'Agostino R.B., Massaro J.M., Sullivan L.M. Non-inferiority trials: design concepts and issues - the encounters of academic consultants in statistics. Stat Med 2003, 22:169-186.
12. Elie C., De Rycke Y., Jais J.P., Marion-Gallois R., Landais P. Methodological and statistical aspects of equivalence and non inferiority trials. Rev Epidemiol Sante Publique 2008, 56:267-277.
13. Ross L.F. Newborn screening for cystic fibrosis: a lesson in public health disparities. J Pediatr 2008, 153:308-313.
14. Roussey M., Le Bihannic A., Scotet V., Audrezet M.P., Blayau M., Dagorne M., et al. Neonatal screening of cystic fibrosis: diagnostic problems with CFTR mild mutations. J Inherit Metab Dis 2007, 30:613.
15. Vernooij-van Langen A.M., Reijntjens S., van der Pal S.M., Loeber J.G., Dompeling E., Dankert-Roelse J.E. To know or not to know, disclosure of a newborn carrier screening test result for cystic fibrosis. Eur J Med Genet 2013, 56:192-196.
16. Comeau A.M., Parad R.B., Dorkin H.L., Dovey M., Gerstle R., Haver K., et al. Population-based newborn screening for genetic disorders when multiple mutation DNA testing is incorporated: a cystic fibrosis newborn screening model demonstrating increased sensitivity but more carrier detections. Pediatrics 2004, 113:1573-1581.
17. Krulisova V., Balascakova M., Skalicka V., Piskackova T., Holubova A., Paderova J., et al. Prospective and parallel assessments of cystic fibrosis newborn screening protocols in the Czech Republic: IRT/DNA/IRT versus IRT/PAP and IRT/PAP/DNA. Eur J Pediatr 2012, 171:1223-1229.
18. Sommerburg O., Krulisova V., Hammermann J., Lindner M., Stahl M., Muckenthaler M., et al. Comparison of different IRT-PAP protocols to screen newborns for cystic fibrosis in three central European populations. J Cyst Fibros 2014, 13:15-23.